3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Neoplasms
3
Venous Thrombosis
2
Venous Thromboembolism
2
Thrombosis
2
Pulmonary Embolism
2
Urinary Tract Infections
1
Unspecified Adult Solid Tumor, Protocol Specific
1
Thromboembolism
1
Staphylococcal Infections
1
Spasm
1
Sleep Initiation and Maintenance Disorders
1
Sepsis
1
Seizures
1
Schizophrenia, Treatment-Resistant
1
Schizophrenia
1
Retinitis
1
Renal Insufficiency, Chronic
1
Pulmonary Arterial Hypertension
1
Prostatic Neoplasms
1
Pneumonia
1
Pancreatic Neoplasms
1
Pain
1
Neutropenia
1
Neoplasms, Plasma Cell
1
Multiple Myeloma
1
Migraine Disorders
1
Menorrhagia
1
Meningitis, Bacterial
1
Meningitis
1
Intraabdominal Infections
1
Interventions
Cyclophosphamide
77
Dexamethasone
74
Melphalan
65
Lenalidomide
50
Bortezomib
50
Peripheral Blood Stem Cell Transplantation
49
fludarabine phosphate
47
Busulfan
46
Filgrastim
39
Tacrolimus
37
Antilymphocyte Serum
33
Radiotherapy
30
Mycophenolic Acid
30
Thalidomide
28
fludarabine
24
Methotrexate
22
Whole-Body Irradiation
21
Cyclosporine
21
Calcium Dobesilate
21
Granulocyte Colony-Stimulating Factor
18
Methylprednisolone
17
Etoposide
17
Cord Blood Stem Cell Transplantation
14
daratumumab
11
Prednisone
11
Carmustine
11
sargramostim
10
Stem Cell Transplantation
10
Sirolimus
10
Rituximab
10
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Neoplasms, Plasma Cell
×
Warfarin
×
Clear all
NCT00790842
2018-10-24
PrE1003
PrECOG, LLC.
Phase 1/2
Terminated
63 enrolled
14 charts